As for the treatment in this patient, a low dose of oral DDAVP was primarily given to manage polyuria, of which is a synthetic analog of the endogenous hormone AVP, but with a 2000–3000 fold lower vasopressor effect.[21] The binding of desmopressin to the G protein-coupled V2 in the collecting duct results in activation of the aquaporin channels by adenylate cyclase increasing cAMP-dependent protein kinase and causing translocation of preformed aquaporin channels to the apical membrane, leading to increased water permeability and osmotic reabsorption of free water. The gene discussed is AVP; the disease is Polyuria.